Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer | Zendy

Mansoor R. Mirza | Zendy; Bradley J. Monk | Zendy; Jørn Herrstedt | Zendy; Amit M. Oza | Zendy; Sven Mahner | Zendy; Andrés Redondo | Zendy; Michel Fabbro | Zendy; Jonathan A. Ledermann | Zendy; Domenica Lorusso | Zendy; Ignace Vergote | Zendy; Noa Ben-Baruch | Zendy; Christian Marth | Zendy; Radosław Mądry | Zendy; René dePont Christensen | Zendy; Jonathan S. Berek | Zendy; Anne Dørum | Zendy; Anna V. Tinker | Zendy; Andreas du Bois | Zendy; Antonio GonzálezMartín | Zendy; Philippe Follana | Zendy; Benedict B. Benigno | Zendy; Per Rosenberg | Zendy; Lucy Gilbert | Zendy; B.J. Rimel | Zendy; Joseph Buscema | Zendy; John Balser | Zendy; Shefali Agarwal | Zendy; Ursula A. Matulonis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Author(s) -

Mansoor R. Mirza,

Bradley J. Monk,

Jørn Herrstedt,

Amit M. Oza,

Sven Mahner,

Andrés Redondo,

Michel Fabbro,

Jonathan A. Ledermann,

Domenica Lorusso,

Ignace Vergote,

Noa Ben-Baruch,

Christian Marth,

Radosław Mądry,

René dePont Christensen,

Jonathan S. Berek,

Anne Dørum,

Anna V. Tinker,

Andreas du Bois,

Antonio GonzálezMartín,

Philippe Follana,

Benedict B. Benigno,

Per Rosenberg,

Lucy Gilbert,

B.J. Rimel,

Joseph Buscema,

John Balser,

Shefali Agarwal,

Ursula A. Matulonis

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1611310

Subject(s) - medicine , hazard ratio , cohort , placebo , parp inhibitor , ovarian cancer , oncology , gastroenterology , confidence interval , cancer , pathology , biology , poly adp ribose polymerase , biochemistry , alternative medicine , polymerase , gene

Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We sought to evaluate the efficacy of niraparib versus placebo as maintenance treatment for patients with platinum-sensitive, recurrent ovarian cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research